TITLE

Update on Influenza A (H1N1) 2009 Monovalent Vaccines

PUB. DATE
October 2009
SOURCE
MMWR: Morbidity & Mortality Weekly Report;10/9/2009, Vol. 58 Issue 39, Special section p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers an update on influenza A (H1N1) monovalent influenza vaccines. Four influenza vaccine manufacturers received approval from the U.S. Food and Drug Administration in September 2009 for use of such vaccines to prevent influenza caused by the 2009 pandemic influenza A (H1N1) virus. These manufacturers include Novartis Vaccines and Diagnostics Ltd., Sanofi Pasteur, Inc., and MedImmune LLC. It is noted that influenza activity caused by 2009 H1N1 viruses increased in September 2009 and is expected to continue in the fall and winter season.
ACCESSION #
58453672

 

Related Articles

  • AFP Edition.  // American Family Physician;1/15/2010, Vol. 81 Issue 2, p103 

    This section offers news briefs related to family medicine in the U.S. as of January 2010. Sanofi Pasteur Inc. recalled its pediatric H1N1 vaccine lots in December 2009 due to decreased potency. The Food and Drug Administration (FDA) notes that production of erythromycin ophthalmic ointment is...

  • FDA Approves Seasonal Flu Vaccine.  // Clinical Infectious Diseases;9/15/2009, Vol. 49 Issue 6, following p993 

    The article reports that the ordinary seasonal flu vaccine has been approved by the U.S. Food & Drug Administration (FDA) and said Americans should plan to be vaccinated. Health experts say that one should be immunized as late as January, as the U.S. influenza season usually peaks in February....

  • What We Learned from H1N1. Part 1: MedImmune.  // BioPharm International;Jul2010, Vol. 23 Issue 7, p13 

    The article focuses on the views of MedImmune Vaccines Inc. executive vice president Ben Machielse on his company's experiences in manufacturing vaccines against H1N1 in the U.S. Machielse delineates that the problem with H1N1 pandemic was the uneven distribution of vaccine. Machielse also...

  • The Moment. Walsh, Bryan // Time International (Atlantic Edition);8/10/2009, Vol. 174 Issue 5, p7 

    The article discusses the H1N1/09 virus and the unpredictability of the number of deaths that the pandemic may cause in the U.S. and elsewhere when the weather gets colder. It notes the considerable adverse effects that have been realized in countries like Argentina where the winter season has...

  • Healthcare Worker Acceptance of Pandemic (H1N1) 2009 Vaccination, Morocco. Tagajdid, Rida; El Annaz, Hicham; Doblali, Taoufik; Sefiani, Kawtar; Belfquih, Bouchra; Mrani, Saad // Emerging Infectious Diseases;Oct2010, Vol. 16 Issue 10, p1638 

    A letter to the editor is presented about a survey of healthcare workers on the acceptance of pandemic H1N1 2009 vaccination in Morocco conducted from January 15 to February 28, 2010.

  • Determinants of adults' intention to vaccinate against pandemic swine flu. Myers, Lynn B.; Goodwin, Robin // BMC Public Health;2011, Vol. 11 Issue 1, p1 

    Background: Vaccination is one of the cornerstones of controlling an influenza pandemic. To optimise vaccination rates in the general population, ways of identifying determinants that influence decisions to have or not to have a vaccination need to be understood. Therefore, this study aimed to...

  • Four different H1N1 vaccines approved.  // Contemporary Pediatrics;Oct2009, Vol. 26 Issue 10, p16 

    The article reports that four pharmaceutical companies have been given approval by the Food and Drug Administration (FDA) in the U.S. for their H1N1 influenza vaccines. All these companies, sanofi pasteur, MedImmune, CSL Ltd. and Novartis Vaccines and Diagnostics, have previous experiences with...

  • Influenza: pandemic scare is potential booster for seasonal flu vaccine market.  // PharmaWatch: Biotechnology;Sep2009, Vol. 8 Issue 9, p25 

    In this article the author discusses the move of Sanofi Pasteur Inc. and CSL Ltd. to start shipping seasonal flu vaccines to health providers in the U.S. The author notes the belief of Datamonitor Group that future sales development in the seasonal influenza vaccine market is a growth pushed by...

  • MedImmune Recalls H1N1 Vaccine.  // BioWorld Today;12/28/2009, Vol. 20 Issue 248, p3 

    The article reports on the decision of MedImmune Inc. to recall 4.7 million doses of its H1N1 nasal flu vaccine in the U.S. According to spokeswoman Sidoney Atse, the move was non-safety related and that there was only a slight decrease in the vaccine potency. It has been noted by the Centers...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics